Seven analysts tracked by S&P Global carry a consensus "Strong Buy" rating on TRLV. Their individual targets range from a low of $15 to a high of $22, and the simple average works out to roughly $18.32, which rounds to the $18.30 central target used here. That wide $15-to-$22 spread reflects genuine disagreement about how quickly federal reform benefits will flow through to earnings.
On the cautious end, ATB Cormark Capital Markets and Cantor Fitzgerald each maintained Buy ratings with $15 targets in early November 2026. More optimistic calls came from Roth MKM's Bill Kirk ($19) and Canaccord Genuity's Luke Hannan ($20), both reaffirmed on November 6, 2026. The reasoning consistently centers on improved cash generation as Schedule III treatment reduces the impact of the 280E tax rule, which previously barred cannabis operators from deducting ordinary business expenses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With a recent close near $10.90 and a market capitalization of about $2.2 billion, TRLV would need to gain roughly 65% to 70% to reach $18.30. By any standard, that is a very large move and not one that typically occurs without a meaningful catalyst. The shares have traded within a 52-week band from about $4.60 to $13.30, so the target sits well above even the recent highs.
The path would likely depend on sustained free-cash-flow generation, a successful ramp of newer state programs, and continued clarity on federal tax treatment. Trailing earnings remain negative, so the valuation case rests heavily on future profitability rather than current results. From what I see, this setup warrants close attention to upcoming catalysts.
Trulieve's third quarter, reported November 5, 2026, showed revenue of $230 million, a 64% gross margin, $89 million in adjusted EBITDA, and $45 million in free cash flow. Final DEA registrations following the rescheduling of state-licensed medical marijuana to Schedule III represent a potentially durable cash-flow tailwind. Georgia's July 1 medical expansion drove a sevenfold increase in store traffic, and royalty-free licenses for the Alien Labs and Connected brands in Florida and Texas add growth optionality. Strong operating cash flow has also allowed the company to repay $65 million in mortgage notes ahead of maturity.
Despite the improving cash picture, TRLV still posts negative trailing earnings per share, and management guidance has been described as cautious, with flatter revenue and higher capital expenditures. Federal tax and regulatory outcomes remain uncertain, and cannabis-sector sentiment can reverse quickly on legislative or legal headlines. A beta near 1.9 means the stock tends to move far more than the broader market in both directions, and the roughly 61% decline in five-year total shareholder return is a reminder of the sector's historical drawdowns.
The 52-week high near $13.30 stands as a notable resistance level, with the $15 floor of the analyst range acting as the next psychological barrier above it. Recent trading has consolidated in the $10 to $12 area, and the $4.60 52-week low marks the lower end of the long-term range. A sustained break above $13 would likely be needed before the market could seriously entertain levels approaching the $18.30 target. I’m watching this closely as technical confirmation could shift the risk-reward profile.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual brokers may differ. Investors should watch quarterly earnings and cash-flow results, any further federal rescheduling or tax developments, the pace of Georgia and Florida program ramps, and analyst target revisions. Changes to state-level adult-use regulations and DEA or legislative actions are the most likely near-term catalysts either way.
Whether TRLV can reach $18.30 depends on whether the cash-flow benefits of federal rescheduling translate into durable, visible profitability. The $18.30 figure is the average of seven analyst targets spanning $15 to $22, reflecting a Strong Buy bias but also genuine disagreement. Strong free cash flow, gross margins, and state expansion support the bull case, while negative earnings, federal uncertainty, and elevated volatility are the principal obstacles. The target requires a roughly two-thirds advance — a substantial ask that will hinge on fundamentals and federal policy rather than momentum alone.
In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to stay on top of fast-moving names like this one. The tool uses artificial intelligence to monitor thousands of stocks and ETFs in real time, delivering Buy, Sell, or Hold signals based on technical behavior and market shifts. For a high-beta stock where sentiment can change quickly, it helps track trends and manage positions without relying solely on manual reviews. I find it useful as part of a broader research routine when evaluating volatility and potential entry points.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
TRLV's Aroon Indicator triggered a bullish signal on November 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 157 similar instances where the Aroon Indicator showed a similar pattern. In 136 of the 157 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +2.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRLV advanced for three days, in 186 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRLV as a result. In 78 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for TRLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 30 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
TRLV moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TRLV crossed bearishly below the 50-day moving average on November 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRLV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
TRLV broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TRLV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.901) is normal, around the industry mean (6.379). P/E Ratio (-4.680) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.470) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.947) is also within normal values, averaging (183.387).
The Tickeron PE Growth Rating for this company is 81 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRLV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PharmaceuticalsGeneric